TDF Linked to Reduced Rate of Hepatocellular Carcinoma in Patients with Cirrhosis
the Cancer Therapy Advisor take:
Patients with hepatitis B virus (HBV) but without cirrhosis, who met treatment criteria, demonstrated a reduced incidence of hepatocellular carcinoma (HCC) while receiving tenofovir disoproxil fumarate (TDF) as long-term therapy, according to an article published online in the journal Cancer.
In the study, the authors used the Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) model to predict risk of HCC in patients for up to 10 years based on age, sex, alanine aminotransferase level, hepatitis B e antigen status, and HBV-DNA.
The authors also calculated standardized incidence ratios (SIRs) to compare the observed and predicted numbers of HCC cases in the study cohort.
Results showed that 482 out of 634 patients, with evaluable baseline biopsies, did not have cirrhosis, while 152 patients did (Ishak fibrosis score of 5 or 6).
In total, 14 cases of HCC were reported during the 384-week study with an overall incidence of HCC of 0.37% per year, 0.28% in patients without cirrhosis, and 0.65% in those with cirrhosis.
Furthermore, the observed incidence of HCC was significantly less than the predicted value (SIR, 0.40; 95% CI: 0.199, 0.795) and the last observed HCC case in a patient with cirrhosis was reported around week 192 (SIR, 0.51; 95% CI: 0.231, 1.144).
Patients demonstrated reduced incidence of hepatocellular carcinoma while receiving tenofovir disoproxil fumarate.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment
- Rare Cancer: An Underserved Area of Oncology
- Pembrolizumab May Benefit Selected Patients With Incurable Metastatic Breast Cancer
- Does Education Level Predict PSA Screening and Prostate Cancer Survival?
- p38 MAPK May Be A Therapeutic Target in Bladder Cancer
- Adjuvant Gefitinib Improves Disease-free Survival Among Patients With NSCLC
- Phase 1 Study of Binimetinib Plus Pexidartinib for GIST
- Phase 2 Study of Nivolumab vs Nivolumab Plus Ipilimumab for GIST
- Pesticides and Cancer
- Goserelin Mitigates Risk of Ovarian Failure, Improves Breast Cancer Survival Rate